Fanconi's Anemia (FA) is a genetic bone marrow failure syndrome that presents in childhood. Congenital malformations and increased cancer risk, particularly acute myelogenous leukemia, are additional manifestations of the disorder. Eighteen distinct genes responsible for the FA phenotype have been identified and together constitute the FA/BRCA network which functions to maintain genome stability and ensure stem cell survival. FA is associated with significant morbidity and early mortality and therapeutic options remain suboptimal. In the past funding period this Program Project succeeded in discovering new drug targets and small molecules for FA therapy. All of these candidates have clinical potential and we are on the threshold of new interventions for this severe disease. The key goal of the project in the next funding period is to prioritize a single drug regimen from our small list of candidates and to generate the preclinical data needed for starting a clinical trial. This Program Project will use a multidisciplinary approach to achieve this goal. The clinical disciplines represented include pediatrics, hematology, oncology and medical genetics. The scientific areas of expertise include molecular hematology, xenotransplantation, DNA repair, cell biology and mouse genetics. Project 1 will explore compounds that have already shown promise in FA mouse models such as metformin, p38 MAPK inhibitors, antioxidants and androgens, both singly and in combination. Project 2 will focus on inhibitors of the TGF-? pathway for the treatment of FA. Project 3 will use primary human cells from FA patients to study the compounds from projects 1 and 2. In addition, the regulatory groundwork for a clinical trial will be done. Core B will evaluate compounds in xenotransplant models of human hematopoiesis. Core C will perform a variety of DNA damage assays in support of all projects. Core D is a biorepository and Core A will provide administrative support.

Public Health Relevance

The significance of this Program Project is very straightforward: Successful completion of our work will result in a clinical trial of a novel small molecule monotherapy or drug combination for Fanconi's Anemia. Furthermore, a treatment regiment that benefits bone marrow failure and delays cancer in FA may well be useful in other forms of aplastic anemia.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL048546-22
Application #
9338273
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Qasba, Pankaj
Project Start
1997-07-01
Project End
2021-05-31
Budget Start
2017-06-01
Budget End
2018-05-31
Support Year
22
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Oregon Health and Science University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Whiteaker, Jeffrey R; Zhao, Lei; Ivey, Richard G et al. (2018) Targeted mass spectrometry enables robust quantification of FANCD2 mono-ubiquitination in response to DNA damage. DNA Repair (Amst) 65:47-53
Kroeger Jr, Paul T; Drummond, Bridgette E; Miceli, Rachel et al. (2017) The zebrafish kidney mutant zeppelin reveals that brca2/fancd1 is essential for pronephros development. Dev Biol 428:148-163
Rondinelli, Beatrice; Gogola, Ewa; YĆ¼cel, Hatice et al. (2017) EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 19:1371-1378
Karras, Georgios I; Yi, Song; Sahni, Nidhi et al. (2017) HSP90 Shapes the Consequences of Human Genetic Variation. Cell 168:856-866.e12
Mouw, Kent W; Goldberg, Michael S; Konstantinopoulos, Panagiotis A et al. (2017) DNA Damage and Repair Biomarkers of Immunotherapy Response. Cancer Discov 7:675-693
Garbati, Michael R; Hays, Laura E; Rathbun, R Keaney et al. (2016) Cytokine overproduction and crosslinker hypersensitivity are unlinked in Fanconi anemia macrophages. J Leukoc Biol 99:455-65
Zhang, Qing-Shuo; Tang, Weiliang; Deater, Matthew et al. (2016) Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood 128:2774-2784
Zhang, Haojian; Kozono, David E; O'Connor, Kevin W et al. (2016) TGF-? Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem Cell 18:668-81
Zhang, Qing-Shuo; Deater, Matthew; Schubert, Kathryn et al. (2015) The Sirt1 activator SRT3025 expands hematopoietic stem and progenitor cells and improves hematopoiesis in Fanconi anemia mice. Stem Cell Res 15:130-40
Xie, Jenny; Kim, Hyungjin; Moreau, Lisa A et al. (2015) RNF4-mediated polyubiquitination regulates the Fanconi anemia/BRCA pathway. J Clin Invest 125:1523-32

Showing the most recent 10 out of 106 publications